Press Releases

Press Releases

Conference Call and Webcast Today at 8:30 a.m. ET Dosing patients in U.S. Phase 2/3 COVAXIN ™ (BBV152) clinical trial Completed dosing of patients in Cohort 1 of OCU400 gene therapy product candidate Expanding product pipeline with the regenerative medicine cell therapy program NeoCart ® MALVERN,
August 5, 2022
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the
June 14, 2022
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will present
June 9, 2022
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will
May 23, 2022